0201 Katie Porter
BioCentury & Getty Images

Politics, Policy & Law

Biopharma execs push back on Rep. Porter’s push to rein in M&A

Congressional report says biopharma acquisitions kill innovation, calls for FTC reviews, restraints. 

A congressional report by California lawmaker Katie Porter says biopharma acquisitions kill innovation, calls for FTC reviews, restraints. 

Feb 2, 2021 | 1:17 AM GMT

Rep. Katie Porter (D-Calif.), a rising voice in the progressive wing of the Democratic Party, has released a report that portrays biopharma mergers and acquisitions as harmful to innovation and recommends laws that would slow or restrict M&A.

The report fundamentally misrepresents the biopharma ecosystem, according to biopharma executives who spoke to

Read the full 1052 word article

How to gain access

Continue reading with a
two-week free trial.